#Canada #Mississauga #Septa Pharmaceuticals #CeeNU #Lomustin

Septa Pharmaceuticals Strengthens Its Portfolio with CeeNU® Acquisition

In a strategic move aimed at expanding its presence in the oncology sector, Septa Pharmaceuticals Inc. has successfully acquired CeeNU® (Lomustin) from Bristol Myers Squibb on June 29, 2026. Known for its commitment to providing specialized medication, Septa is rapidly gaining recognition as a leader in the Canadian healthcare industry.

CeeNU® (Lomustin), a well-established alkylating agent, plays a critical role in treating certain types of brain tumors as well as Hodgkin’s lymphoma. By integrating this respected chemotherapeutic agent into its product lineup, Septa bolsters its capabilities in intensive care and oncology, reaffirming its dedication to improving patient outcomes.

Devinder K., President and CEO of Septa Pharmaceuticals Inc., emphasized the importance of this acquisition, stating, "As we incorporate CeeNU® into our expanding portfolio, our primary focus continues to be on the patients and the healthcare professionals who care for them. We are working closely with all relevant stakeholders, including regulatory authorities and supply chain partners, to ensure a seamless transition."

The integration of CeeNU® is not just a business operation; it reflects Septa’s profound commitment to ensuring patients across Canada have uninterrupted access to life-saving medications. In today’s complex healthcare landscape, where the necessity for reliable and stable supplies of essential drugs is crucial, Septa prioritizes the long-term availability of CeeNU® to meet these demands.

Septa's acquisition comes at a time when the global healthcare market is experiencing rapid changes, demanding innovative solutions and enduring commitment from pharmaceutical companies. Septa remains vigilant in its pursuit of expanding product offerings with an emphasis on customer needs. Additionally, with its diverse portfolio expanding at a swift pace, the company is actively seeking new strategic partnerships and licensing opportunities to introduce effective therapies to markets worldwide.

"This acquisition exemplifies our core mission of providing high-quality, reliable pharmaceutical products that significantly enhance health outcomes both nationally and globally," added K.

As Septa Pharmaceuticals progresses, it is dedicated to addressing market gaps and stabilizing the supply of vital medicines through strategic partnerships and targeted acquisitions. Such efforts are aimed at ensuring that medications not only reach the market but also meet the evolving needs of the global healthcare community.

In summary, with the acquisition of CeeNU®, Septa Pharmaceuticals positions itself as a pivotal player in the Canadian healthcare arena, committed to improving patient care and enhancing treatment options for serious health conditions. The company is focused on creating sustainable pathways that allow crucial therapies to be accessible worldwide, ensuring a better future for patients facing significant health challenges.

For more information about Septa Pharmaceuticals and its growing portfolio, please visit their website or contact their press office.